Similar articles

• Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C.

  Ciancio A, Ribaldone DG, Sacco M, Saracco GM. Ciancio A, et al. Liver Int. 2021 Mar;41(3):640. doi: 10.1111/liv.14738. Epub 2020 Dec 2. Liver Int. 2021. PMID: 33222363 No abstract available.
• Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.

  Radhakrishnan S, Upadhyay A, Mohan N, Dhar A, Walia HK, Zubaidi G. Radhakrishnan S, et al. Med Princ Pract. 2005 Jul-Aug;14(4):281-3. doi: 10.1159/000085751. Med Princ Pract. 2005. PMID: 15961942
• Diabetes mellitus during interferon therapy for chronic viral hepatitis.

  Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, Demontis R, Cadranel JF. Mofredj A, et al. Dig Dis Sci. 2002 Jul;47(7):1649-54. doi: 10.1023/a:1015852110353. Dig Dis Sci. 2002. PMID: 12141831 Review. No abstract available.
• Massive increase of insulin resistance in a patient with chronic hepatitis C after treatment with interferon.

  Chatterjee S. Chatterjee S. J Assoc Physicians India. 2004 Jun;52:514. J Assoc Physicians India. 2004. PMID: 15645973 No abstract available.
• Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin.

  Barnes E, Webster G, Jacobs R, Dusheiko G. Barnes E, et al. J Hepatol. 1999;31 Suppl 1:244-9. doi: 10.1016/s0168-8278(99)80410-3. J Hepatol. 1999. PMID: 10622596 Review.